Fig. 4: PFS for individual patients in the dose-expansion phase (tumour response analysis set). | British Journal of Cancer

Fig. 4: PFS for individual patients in the dose-expansion phase (tumour response analysis set).

From: A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

Fig. 4

Baseline PD-L1 TC ≥20% was indicative of high PD-L1 expression. AE adverse event, EGFR epidermal growth factor receptor, H high (PD-L1 TC ≥20%), L low/negative (PD-L1 TC <20%), NE not evaluable (no sample or <100 TCs), PD-L1 programmed cell death ligand-1, PFS progression-free survival, TC tumour cell.

Back to article page